CIBRN Poll #6: Which of these issues in the Canadian drug access and pricing landscape is of greatest concern to you as a clinician?

If you haven’t yet participated, we invite you to share your views in the following poll. Click here to answer.

CIBRN Poll #6: Which of these issues in the Canadian drug access and pricing landscape is of greatest concern to you as a clinician?

Seismic changes are happening or being considered in the Canadian drug access and pricing landscape. Issues include recurring drug shortages, possible implementation of a national pharmacare program, American importation of Canadian drugs, and changes to PMPRB legislation designed to reduce Canadian prices for new drugs entering the market.

Which of these issues is of greatest concern to you as a clinician?

  • Drug shortages of established products, many now genericized and often made by only 1 or a few manufacturers, due to manufacturing issues.
  • The cost to indebted governments of establishing a national pharmacare program.
  • Delays in the launch of innovative drugs due to lower Canadian market prices under the new PMPRB rules.
  • Drug shortages in Canada due to Americans importing drugs from Canada to take advantage of lower Canadian prices.

Click here to answer